What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Hims & Hers Health, Inc. (HIMS) Alleged “Deceptive” Marketing of Wegovy® Triggers Securities Class Actions – HIMS Investors with Losses Encouraged to Contact Hagens Berman ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...